Home > Oncology > ASCO GU 2022 > Renal Cell Carcinoma > Combined nivolumab/axitinib treatment elicits good response in metastatic RCC

Combined nivolumab/axitinib treatment elicits good response in metastatic RCC

Presented By
Dr Matthew Zibelman, Fox Chase Cancer Center, PA, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GU 2022
Trial
Phase 1/2
Combination treatment with the immune checkpoint inhibitor nivolumab plus the tyrosine kinase inhibitor (TKI) axitinib achieved a high response rate in treatment-naïve patients with metastatic renal cell carcinoma (mRCC) in a recent phase 1/2 trial. A combination of systemic therapy with TKIs and immune checkpoint inhibitors is an established standard of care for patients with metastatic RCC. Several trials with different combinations are currently ongoing. Dr Matthew Zibelman (Fox Chase Cancer Center, PA, USA) presented the first results of a phase 1/2 study (NCT03172754) investigating the safety and efficacy of the TKI axitinib combined with the immune checkpoint inhibitor nivolumab [1]. The trial was initiated before the results from various phase 3 studies of immune checkpoint inhibitor/TKI combinations were known. In the phase 1 part, the recommended d...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on